Neurobiology of Aging
Volume 28, Issue 3 , Pages 336-342 , March 2007

Determinants of platelet activation in Alzheimer's disease

  • Giovanni Ciabattoni

      Affiliations

    • Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Italy
    • Department of Drug Sciences, University of Chieti “G. d’Annunzio”, School of Pharmacy, Italy
    • ,
  • Ettore Porreca

      Affiliations

    • Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Italy
    • Department of Medicine, University of Chieti “G. d’Annunzio”, School of Medicine, Italy
    • ,
  • Concetta Di Febbo

      Affiliations

    • Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Italy
    • Department of Medicine, University of Chieti “G. d’Annunzio”, School of Medicine, Italy
    • ,
  • Angelo Di Iorio

      Affiliations

    • Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Italy
    • Department of Medicine, University of Chieti “G. d’Annunzio”, School of Medicine, Italy
    • ,
  • Roberto Paganelli

      Affiliations

    • Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Italy
    • Department of Medicine, University of Chieti “G. d’Annunzio”, School of Medicine, Italy
    • ,
  • Tonino Bucciarelli

      Affiliations

    • Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Italy
    • Department of Medicine, University of Chieti “G. d’Annunzio”, School of Medicine, Italy
    • ,
  • Lea Pescara

      Affiliations

    • Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Italy
    • Department of Medicine, University of Chieti “G. d’Annunzio”, School of Medicine, Italy
    • ,
  • Letizia Del Re

      Affiliations

    • Department of Geriatrics, Civil Hospital Pescara, Italy
    • ,
  • Cinzia Giusti

      Affiliations

    • Department of Laboratory Medicine, Civil Hospital Pescara, Italy
    • ,
  • Angela Falco

      Affiliations

    • Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Italy
    • Department of Medicine, University of Chieti “G. d’Annunzio”, School of Medicine, Italy
    • ,
  • Antonella Sau

      Affiliations

    • Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Italy
    • Department of Medicine, University of Chieti “G. d’Annunzio”, School of Medicine, Italy
    • ,
  • Carlo Patrono

      Affiliations

    • Department of Pharmacology, University of Rome “La Sapienza”, II Facoltà di Medicina e Chirurgia, Via di Grottarossa 1035, 00189 Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0871 541260; fax: +39 0871 541261.
    • ,
  • Giovanni Davì

      Affiliations

    • Center of Excellence on Aging, “G. d’Annunzio” University Foundation, Italy
    • Department of Medicine, University of Chieti “G. d’Annunzio”, School of Medicine, Italy

Received 3 August 2005 ,Revised 7 December 2005 ,Accepted 20 December 2005.

References 

  1. Borroni B, Akkawi N, Martini G, Colciaghi F, Prometti P, Rozzini L, et al. Microvascular damage and platelet abnormalities in early Alzheimer's disease. J Neurol Sci. 2002;204:189–193
  2. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet. 2004;363:1139–1146
  3. Catella F, Healy D, Lawson JA, FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA. 1986;83:5861–5865
  4. Ciabattoni G, Pugliese F, Davì G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B2 to urinary 11-dehydro-thromboxane B2 in man. Biochim Biophys Acta. 1989;992:66–70
  5. Ciabattoni G, Maclouf J, Catella F, FitzGerald GA, Patrono C. Radioimmunoassay of 11-dehydro-thromboxane B2 in human plasma and urine. Biochim Biophys Acta. 1987;918:293–297
  6. Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322:1769–1774
  7. Davì G, Averna M, Catalano I, Barbagallo C, Ganci A, Notarbartolo A, et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation. 1992;85:1792–1798
  8. Davì G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis in man. Chem Phys Lipids. 2004;128:149–163
  9. de la Torre JC. Alzheimer's disease as a vascular disorder: nosological evidence. Stroke. 2002;33:1152–1162
  10. Di Minno G, Davì G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993;92:1400–1406
  11. Feillet-Coudray C, Tourtauchaux R, Niculescu M, Rock E, Tauveron I, Alexandre-Gouabau MC, et al. Plasma levels of 8-epi-PGF2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic Biol Med. 1999;27:463–469
  12. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676–688
  13. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–442
  14. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  15. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281–291
  16. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al. Stroke and the risk of Alzheimer disease. Arch Neurol. 2003;60:1707–1712
  17. Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med. 2004;14:18–22
  18. Jones RW. Inflammation and Alzheimer's disease. Lancet. 2001;358:455–461
  19. Lawson JA, Patrono C, Ciabattoni G, Fitzgerald GA. Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. Anal Biochem. 1986;155:198–205
  20. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem. 1998;35:745–753
  21. Lee BL, Chua SC, Ong HY, Ong CN. High-performance liquid chromatographic method for routine determination of Vitamins A and E and beta-carotene in plasma. J Chromatogr. 1992;581:41–47
  22. Li QX, Berndt MC, Bush AI, Rumble B, Mackenzie I, Friedhuber A, et al. Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet. Blood. 1994;84:133–142
  23. Lombardi VR, Garcia M, Rey L, Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease (AD) individuals. J Neuroimmunol. 1999;97:163–171
  24. McAdam BF, Byrne D, Morrow JD, Oates JA. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation. 2005;112:1024–1029
  25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  26. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ, Morrow JD, et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids. 2004;128:117–124
  27. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol. 2002;52:175–179
  28. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383–9387
  29. Orlandi M, Bartolini G, Belletti B, Spisni E, Tomasi V. Thromboxane A2 synthase activity in platelet free human monocytes. Biochim Biophys Acta. 1994;1215:285–290
  30. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366–1372
  31. Patrignani P, Santini G, Panara MR, Sciulli MG, Greco A, Rotondo MT, et al. Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F2-isoprostane formation. Br J Pharmacol. 1996;118:1285–1293
  32. Patrono C, Davì G, Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc Med. 1992;2:15–20
  33. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383
  34. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997;17:2309–2315
  35. Praticò D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2α. J Biol Chem. 1995;270:9800–9808
  36. Praticò D, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation. FASEB J. 1998;12:1777–1784
  37. Praticò D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8, 12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol. 2000;48:809–812
  38. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002;99:7634–7639
  39. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336:1216–1222
  40. Skovronsky DM, Lee VM, Praticò D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem. 2001;276:17036–17043
  41. Tedgui A, Mallat Z. Platelets in atherosclerosis: a new role for beta-amyloid peptide beyond Alzheimer's disease. Circ Res. 2002;90:1145–1146
  42. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996;380:168–171
  43. van Kooten F, Ciabattoni G, Koudstaal PJ, Grobbee DE, Kluft C, Patrono C. Increased thromboxane biosynthesis is associated with poststroke dementia. Stroke. 1999;30:1542–1547
  44. Waddington E, Croft K, Clarnette R, Mori T, Martins R. Plasma F2-isoprostanes levels are increased in Alzheimer's disease: evidence of increased oxidative stress in vivo. Alzheimers Rep. 1999;2:277–282
  45. Wang Z, Ciabattoni G, Créminon C, Lawson J, Fitzgerald GA, Patrono C, et al. Immunological characterization of urinary 8-epi-PGF2 excretion in man. J Pharmacol Exp Ther. 1995;275:94–100
  46. Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP, Selkoe DJ. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol. 1992;141:249–259
  47. Zubenko GS, Winwood E, Jacobs B, Teply I, Stiffler JS, Hughes HB, et al. Prospective study of risk factors for Alzheimer's disease: results at 7.5 years. Am J Psychiat. 1999;156:50–57

☆ All authors disclose any actual or potential conflicts of interest including any financial, personal or other relationships with other people or organizations within 3 years of beginning the work that could inappropriately influence it. The study was approved by the Medical Ethics Committee of the “G. d’Annunzio” University Medical School and conducted according to the principles of the Helsinki Declaration.

PII: S0197-4580(05)00456-2

doi: 10.1016/j.neurobiolaging.2005.12.011

Neurobiology of Aging
Volume 28, Issue 3 , Pages 336-342 , March 2007

Article Tools

* Image Usage & Resolution